Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes.

Klaus K WitteMichael DrozdAndrew M N WalkerPeysh A PatelJessica C KearneySally ChapmanRobert J SapsfordJohn GierulaMaria F PatonJudith LowryMark T Kearney Richard M Cubbon

Published in: Diabetes care (2017)

Increasing β-blocker dose is associated with a greater prognostic advantage in CHF patients with diabetes than in CHF patients without diabetes.

Keyphrases

ejection fraction
end stage renal disease
type diabetes
cardiovascular disease
newly diagnosed
peritoneal dialysis
prognostic factors
cardiovascular events
adipose tissue
metabolic syndrome
coronary artery disease
angiotensin ii
patient reported